🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Arbutus Biopharma Corporation ABUS R2KR3KPHARMA

Healthcare · Biotechnology · United States
https://www.arbutusbio.com
Company Profile ↓
$5.15
+52.82% 1Y
Mkt Cap$1.02B
P/E6.20
P/B3.50
52W High$5.22
52W Low$3.37
Book Value$1.32
EPS (TTM)$0.83

Company Overview

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 94.7%, reflecting efficient use of shareholder capital.

Consistent Profit Growth

Net profit has compounded at 17.3% per year over the last five years.

Reasonable Valuation

Trades at a P/E of 6.2, below the sector median of 25.2.

Healthy Margins

Maintains a net profit margin of 84.0%.

Recent Developments

  • Dec 2025 Revenue of $14.08M (+128.2% YoY); net profit $-33.50M.
  • 5-Year Trend Long-term compounding — revenue CAGR -28.8%, profit CAGR 17.3%.

Growth & Price Performance

Compounded Sales Growth

5 Years:-28.80%
1 Year:-

Compounded Profit Growth

5 Years:17.26%
1 Year:-

Stock Price Performance

1 Year:+52.82%
6 Months:+13.69%
3 Months:+21.18%
1 Month:+13.44%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 96% of range
$3.37 $5.22
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)63.06 · Neutral
Price Performance
1M+13.44%
3M+21.18%
6M+13.69%
1Y+52.82%
Valuation vs Sector

P/E of 6.20 is below the sector median of 25.17 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Strong return on equity of 94.7%.
  • Excellent profit margin of 84.0%.
  • Profit CAGR of 17.3% over 5 years.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Revenue declined at -28.8% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
6.20
Industry PE
25.17
Forward P/E
-31.16
PEG Ratio
-
Book Value
$1.32
Price to Book
3.50
P/S
4.76
EV/EBITDA
5.31
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
-28.80%
Profit 5Y
17.26%
Revenue (YoY)
-
Earnings (YoY)
-

Profitability & Returns

ROCE
-30.53%
ROE
94.73%
ROA
49.18%
Profit Margin
83.95%
Op Margin
94.41%
Gross Margin
89.34%
EPS (Latest Qtr)
$0.87
EPS (TTM)
$0.83

Balance Sheet & Liquidity

Debt/Equity
1.50
Quick Ratio
54.00
Current Ratio
54.26
Debt
$3.91M
Total Assets
$277.16M
Current Assets
$277.01M
Working Capital
$88.45M

Ownership

Promoter Holding
20.40%
Chg in Prom Hold
-0.03%
FII / Inst Holding
72.25%
Chg in FII Hold
-0.02%

Financial Snapshot

Enterprise Value
$1.02B
Total Revenue (TTM)
$191.44M
EBITDA
$155.14M
Free Cash Flow
$-90.41M
Operating Cash Flow
$-34.36M
Shares Outstanding
197.54M
Gross Margin
89.34%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 ABUS Arbutus Biopharma Corporation R2KR3KPHARMA 5.15 6.20 $1.02B 0.00% -30.53% 94.73% -28.80% 17.26%
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,149.36 38.57 $1.02T 0.58% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 275.23 31.97 $663.28B 2.09% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 256.46 72.45 $453.19B 2.84% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 150.33 120.26 $371.29B 2.65% - 34.70% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 397.14 25.54 $356.47B 2.33% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 159.99 24.20 $304.10B 3.03% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 162.70 24.36 $252.33B 1.98% 15.97% 21.96% 9.82% 45.96%
9 AMGN Amgen Inc. NDXSPXR3KPHARMA 437.23 27.14 $235.98B 2.49% 13.95% 91.47% 5.51% 5.55%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Mar 2015Jun 2015Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 4.68M3.44M4.07M12.69M603.00K309.00K774.00K-195.00K235.00K1.04M6.89M2.53M1.44M1.24M1.59M1.68M679.00K653.00K3.06M1.62M1.49M1.51M1.52M2.11M2.33M3.34M12.58M14.24M5.95M6.69M4.65M4.66M1.53M1.73M-1.76M10.74M529.00K1.05M179.13M
Cost of Revenue ----------------------------------------
Gross Profit ----------------------------------------
Operating Expenses -----------------------------------14.79M8.83M8.82M8.70M10.01M
Operating Income -18.01M-14.42M-58.14M-11.76M-19.98M-195.25M-18.98M-257.44M-18.30M-19.48M-12.90M-60.25M-18.41M-22.05M-32.43M-16.90M-19.20M-20.64M-91.03M-13.09M-13.15M-13.14M-15.22M-15.68M-18.64M-18.41M-10.97M-14.11M-17.81M-17.41M-18.39M-21.56M-19.36M-21.58M--13.03M1.91M-8.29M-7.64M169.12M
EBITDA ------------------------------------24.17M2.56M-7.71M-3.73M169.72M
Interest Expense -----------------------------------28.00K28.00K23.00K18.00K17.00K
Pretax Income ------------------------------------24.53M2.52M-7.74M-3.76M169.69M
Tax Provision ----------------------------------------
Net Income -11.99M-14.89M-28.98M-5.26M-15.87M-130.00M-19.59M-218.69M-18.63M-18.25M-11.60M-35.93M-17.43M3.09M-24.47M-18.25M-23.25M-23.32M-82.50M-24.65M-13.86M-14.09M-18.75M-16.38M-19.39M-19.16M-15.77M-14.19M-17.57M-16.34M-17.09M-20.10M-17.88M-19.80M--24.53M2.52M-7.74M-3.76M169.69M
Diluted EPS ----------0.33---0.360.01-0.49-0.38--0.46---0.25-0.25-0.27-0.21-0.23-0.24-0.11-0.10-0.12-0.10-0.10-0.12-0.10-0.11-0.10-0.130.01-0.04-0.87
R&D Expense 10.56M9.69M16.35M-13.14M15.21M15.74M-13.87M15.45M15.54M-13.95M16.36M16.57M-14.71M12.74M17.73M-10.42M10.46M12.06M13.78M15.80M16.71M18.46M22.94M20.05M18.27M17.69M20.17M15.40M15.55M14.27M8.96M5.50M5.78M-4.12M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 16.81M14.11M15.46M14.95M23.28M1.49M10.70M5.95M6.01M6.91M-39.02M18.14M6.17M14.08M
Cost of Revenue ---------------
Gross Profit ---------------
Operating Expenses -----------102.24M96.17M76.14M41.13M
Operating Income -10.69M-12.95M-12.15M-33.43M-103.92M-491.64M-110.93M-89.78M-143.90M-57.81M--63.22M-78.03M-69.97M-27.05M
EBITDA ------------61.86M-70.99M-68.40M-33.04M
Interest Expense -----------1.73M459.00K137.00K97.00K
Pretax Income ------------65.01M-72.85M-69.92M-33.50M
Tax Provision ----------04.44M00-
Net Income -10.08M29.61M-14.06M-38.84M-62.72M-384.16M-84.41M-57.06M-153.72M-63.74M--69.46M-72.85M-69.92M-33.50M
Diluted EPS -0.892.07-0.92-1.80-1.38-7.24-1.56-1.21--1.00--0.46-0.44-0.38-0.17
R&D Expense 20.13M18.04M21.46M38.71M51.51M61.25M62.68M57.93M57.60M49.34M65.50M84.41M73.70M54.04M25.24M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets ---71.72M118.18M712.29M275.92M237.16M227.91M105.53M137.08M-195.42M144.40M131.71M94.62M
Current Assets ------------151.14M132.03M127.32M94.46M
Cash & Equivalents 12.41M9.03M47.02M68.72M72.19M166.78M23.41M54.29M36.94M31.80M52.25M-30.78M26.29M36.33M18.01M
Inventory ----------------
Receivables ------------1.35M1.78M2.41M1.45M
Total Liabilities ---12.52M30.14M164.61M72.91M54.69M27.67M32.79M35.11M-58.57M38.38M34.34M18.04M
Current Liabilities ---12.52M20.21M10.58M10.59M14.63M11.24M7.83M9.54M-32.86M22.49M15.62M6.01M
Long Term Debt ----------------
Total Debt ------------2.19M1.77M1.29M746.00K
Total Equity 10.79M5.23M40.92M59.19M88.03M547.68M203.00M182.47M200.23M72.74M101.97M-136.85M106.02M97.37M76.58M
Shares Outstanding ------------157.46M169.87M189.96M192.53M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -7.83M32.91M-6.74M-12.42M-56.38M-57.88M-48.64M-67.87M-71.01M-51.44M--35.36M-85.94M-64.85M-39.64M
Investing Cash Flow -60.38K-12.00K-725.00K-42.96M7.68M-99.12M27.82M-4.13M28.34M-14.91M--74.94M50.77M22.95M15.58M
Financing Cash Flow 4.61M4.55M32.72M60.68M143.87M12.64M49.32M55.65M37.46M86.75M-31.81M30.65M52.00M5.72M
Capital Expenditure -60.38K-15.00K-725.00K-1.06M-2.29M-4.00M-7.26M-1.14M-589.00K-229.00K-809.00K-512.00K-1.01M-182.00K-
Free Cash Flow -7.89M32.89M-7.46M-13.48M-58.67M-61.88M-55.90M-69.00M-71.59M-51.67M--35.87M-86.94M-65.03M-39.64M
Net Change in Cash ------------78.48M-4.52M10.09M-18.34M

Ratios (Annual)

Figures in %.

Metric Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % ---------------
Operating Margin % -63.6%-91.8%-78.6%-223.6%-446.5%-32,973.8%-1,036.7%-1,510.2%-2,394.0%-836.1%--162.0%-430.2%-1,133.9%-192.1%
Net Margin % -60.0%209.9%-90.9%-259.7%-269.5%-25,765.5%-788.9%-959.8%-2,557.4%-922.0%--178.0%-401.6%-1,133.0%-237.9%
ROE % -192.9%72.4%-23.8%-44.1%-11.5%-189.2%-46.3%-28.5%-211.3%-62.5%--50.8%-68.7%-71.8%-43.7%
ROCE % ---20.5%-34.1%-14.8%-185.3%-49.8%-41.4%-147.3%-45.3%--38.9%-64.0%-60.3%-30.5%

Shareholding Pattern

Insiders
20.40%
Institutions
72.25%
Public Float
90.77%

Top Institutional Holders

#Holder% HeldSharesValue
1 Two Seas Capital Lp 9.64% 19.10M $96.81M
2 Morgan Stanley 8.93% 17.70M $89.73M
3 Whitefort Capital Management, LP 7.97% 15.79M $80.08M
4 Blackrock Inc. 6.95% 13.77M $69.79M
5 State Street Corporation 3.97% 7.87M $39.90M
6 Rubric Capital Management LP 3.80% 7.53M $38.19M
7 Vanguard Capital Management LLC 3.54% 7.01M $35.54M
8 Barclays Plc 2.12% 4.21M $21.33M
9 Geode Capital Management, LLC 2.08% 4.12M $20.88M
10 Goldman Sachs Group Inc 1.77% 3.51M $17.78M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ABUS

Yahoo Finance Fri, 21 Aug 2026

Arbutus Biopharma shares jump after unveiling $230 million share buyback plan

Arbutus Biopharma Corporation (NASDAQ:ABUS) shares climbed 10. 3% in premarket trading on Friday after the biotechnology company announced plans to repurchase up to $230 million of its common stock through a modified Dutch auction tender of…

Yahoo Finance Fri, 21 Aug 2026

Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender Offer

WARMINSTER, Pa., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced plans to commence a modi…

Yahoo Finance ue, 11 Aug 2026

Could Arbutus Biopharma Corporation (ABUS) Turn its Moderna, Inc. (MRNA) Settlement Into a Lasting Biotech Advantage?

A landmark legal settlement in the biotech sector recently reshaped the financial trajectories of two key mRNA technology players: Arbutus Biopharma Corporation (NASDAQ:ABUS) and Moderna, Inc. (NASDAQ:MRNA). The resolution of their global p…

Yahoo Finance Fri, 17 Jul 2026

Arbutus, Sanofi escalate mRNA patent fights; InnoCare’s TYK2 contender advances

The new lawsuits add to a web of legal disputes over technology involved in COVID vaccines. Elsewhere, a prolific AI biotech inked another deal and Insmed strengthened support for a closely watched blood pressure drug.…

Yahoo Finance hu, 16 Jul 2026

ABUS Stock On Track For Best Day In About Two Months — What’s The Moderna Connection?

On July 8, Arbutus received around $178 million from Moderna as part of a patent litigation settlement, the company said.

Yahoo Finance hu, 16 Jul 2026

Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders

Arbutus and its exclusive licensee, Genevant, filed three international lawsuits seeking to enforce patents protecting their innovative lipid nanoparticle (“LNP”) technology against Pfizer and BioNTech Received approximately $178M from Mode…

ABUS — Frequently Asked Questions

What is the current share price of Arbutus Biopharma Corporation (ABUS)?

As of 2026-09-07 16:24 PDT, Arbutus Biopharma Corporation (ABUS) trades at $5.15 on NasdaqGS. Its 52-week range is $3.37 to $5.22.

What is the market capitalisation of ABUS?

Arbutus Biopharma Corporation (ABUS) has a market capitalisation of $1.02B on NasdaqGS.

What is the P/E ratio of ABUS?

ABUS trades at a trailing price-to-earnings (P/E) ratio of 6.20. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 3.50.

What is the return on equity (ROE) of ABUS?

ABUS has a return on equity (ROE) of 94.73%. Its return on capital employed (ROCE) is -30.53%.

Is ABUS a good stock to buy?

This page provides a data-driven analysis of Arbutus Biopharma Corporation (ABUS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space